BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250410T190000
DTEND;TZID=Africa/Nairobi:20250410T203000
DTSTAMP:20260527T105725
CREATED:20250407T135020Z
LAST-MODIFIED:20250622T144124Z
UID:24249-1744311600-1744317000@kesho-kenya.org
SUMMARY:Esophageal Cancer CME
DESCRIPTION:[vc_row][vc_column][vc_column_text]Esophageal Cancer CME – Experience from a Regional Cancer Centre \nModerator: Dr Tracy Irura \nSpeakers & Topics: \n\nDr Omar Abdihamid: Evolving Landscape of Esophageal Cancer Treatment\nDr Abdullahi Hadi: Optimising Diagnosis of Esophageal Cancer\nDr Mohamed Noor: Surgical Approaches to Esophageal Cancer\n\nDr. Noor Mohamed provided a historical evolution of esophageal cancer surgery from Czerny’s resection to modern minimally invasive techniques.\n– Surgical resection remains critical\, especially for early-stage and select advanced cases after neoadjuvant therapy.\n– Key considerations include thorough staging (OGD\, PET-CT\, EUS)\, patient optimization (nutrition\, glycemic control)\, and perioperative care.\n– Outcomes from global surgical databases: R0 resection rates up to 93%\, 30- and 90-day mortality rates at 2% and 4.5% respectively.\n– Challenges in Kenya include late presentation\, limited access to ICU care\, and lack of trained personnel.\n– Trials such as CROSS\, PreSANO\, and SANO are shaping modern surveillance versus resection decisions in select cases. \nDr. Omar Abdihamid – emphasized that most patients in Kenya present with locally advanced disease; male/female incidence is similar.\n– Immunotherapy has shifted paradigms: CheckMate 648 showed improved OS with nivolumab + chemotherapy or ipilimumab.\n– CROSS and ESOPEC trials guide perioperative regimens (carbo/taxol RT → surgery → nivolumab vs FLOT-based therapy).\n– Early-stage SCC may be treated with endoscopic resection if well-differentiated\, superficial\, and no lymphovascular invasion.\n– Radiotherapy regimens tailored by location: cervical tumors dose-escalated up to 60Gy; others typically 50.4Gy.\n– Garissa Cancer Centre approach includes advanced IMRT planning\, with regional data contributing to genomic and QoL research.\n– SANO trial supports non-inferiority of active surveillance post-chemoradiotherapy\, showing similar OS to surgery and better QoL.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/esophageal-cancer-cme/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME),Symposia and Workshops
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250407-WA0000-e1746480214833.jpg
END:VEVENT
END:VCALENDAR